People: Neptune Technologies & Bioressources Inc (NEPT.PH)


NEPT.PH on Philadelphia Stock Exchange

3.02USD
3:46pm EDT
Price Change (% chg)

$0.09 (+3.07%)
Prev Close
$2.93
Open
$2.92
Day's High
$3.02
Day's Low
$2.92
Volume
1,600
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Summary

Name Age Since Current Position

Ronald Denis

 Independent Chairman of the Board

Henri Harland

 1998 President, Chief Executive Officer, Director

Andre Godin

 2012 Chief Financial Officer

Michel Chartrand

 2011 Chief Operating Officer, Director

Fotini Sampalis

 2012 Chief Global Strategy Officer

Harlan Waksal

 59 2012 Director

Jean-Claude Debard

 2009 Independent Director

Daniel Perry

 2000 Independent Director
» Insider Trading

Biographies

Name Description

Ronald Denis

 Dr. Ronald Denis is Independent Chairman of the Board of Neptune Technologies & Bioressources Inc. Dr. Ronald Denis has been Chief of Surgery and director of the Trauma Program at Hôpital du Sacré-Coeur in Montréal since 1997. Since 1987, Dr. Denis has also been medical co-director of the Canadian Formula 1 Grand Prix. Dr. Denis sits on several scientific boards and management committees.

Henri Harland

 Mr. Henri Harland is President, Chief Executive Officer, Director of Neptune Technologies & Bioressources Inc. He has served as a Director and the President and Chief Executive Officer of the company since its incorporation in 1998. He has been involved in the krill research project since 1991 and was a pioneer in foreseeing its nutraceutical and pharmaceutical applications, as well as its potential role in nutrigenomics. Over time, Mr. Harland’s vision, passion, dedication, creativity and leadership have resulted in building Neptune and creating the remarkable product that Neptune Krill Oil™ is today. Since 1998, he has held the position of President and Chief Executive Officer of Groupe Conseil Harland inc., a financial engineering group. From May 1992 to September 1997, Mr. Harland was a Director and acted as Vice-President of Corporate Development and Chief Financial Officer of SignalGene Inc. (formerly Société Algène Biotechnologies Inc.), a publicly traded biotechnology corporation.

Andre Godin

 Mr. Andre Godin C.A., serves as the Chief Financial Officer of Neptune Technologies & Bioressources Inc. Mr. Godin has a Bachelor in Administration and has been a Member of the Canadian Institute of Chartered Accountants since 1988. He has more than 10 years experience in the Biotech/Pharma industry as former President of a Dietary Supplement Corporation and as a Corporate Controller for a pharmaceutical Corporation in OTC products.

Michel Chartrand

 Mr. Michel Chartrand is Chief Operating Officer, Director of Neptune Technologies & Bioressources Inc. On September 12, 2011, Mr. Michel Chartrand joined the Corporation has its Chief Operating Officer. Before joining the Corporation, he was the Vice-President of Retail Partner Solutions at McKesson Canada between 2009 and 2011. From 2004 to 2009 Mr. Chartrand was the President and Chief Executive Officer of Groupe PharmEssor inc. which included, due to a merger, Gestion Santé Services Obonsoins Inc. and Groupe Essaim Inc., two important Quebec pharmacy franchisors in Quebec. From 1998 to 2004, Mr. Chartrand was the Executive Vice President of Gestion Santé Services Obonsoins Inc.

Fotini Sampalis

 Dr. Fotini Sampalis M.D., Ph.D., is Chief Global Strategy Officer of Neptune Technologies & Bioressources Inc. Dr. Sampalis is an Oncology Surgeon, trained in Physiology at McGill University, Medicine at the University of Patras (Greece), Dermatology at Göttingen University (Germany) and Marselisborg University (Denmark), Pediatric, General and Oncology Surgery at the University of Athens (Greece), graduate training (PhD) in Surgical Research at the University of Athens and a second PhD in Epidemiology and Experimental Surgery at McGill University. She has received several international scholarships and awards for her work on the clinical implementation of retinols skin and breast cancer including the Helen Hutchison Award for geriatric medicine. Her work on Scintimammography resulted in her appointment at the International Educational Speakers Bureau, the Canadian and U.S. Faculty of Medical Speakers for Breast Imaging. As an international scholar she leads the development and implementation of innovative micro-invasive and stereotactic robotic surgical techniques for breast cancer, for which a USA and Canadian patent application has been filed. She is a member of the American Association of Naturopathic Medicine. Dr. Sampalis has published in multiple peer reviewed publications.

Harlan Waksal

 Dr. Harlan W. Waksal, M.D., is Director of Neptune Technologies & Bioressources Inc., since May 23, 2012. Dr. Harlan W. Waksal is a retired physician. Dr. Waksal is the Vice-President, Business and Scientific Affairs at Acasti Pharma Inc. He received his B.A. from Oberlin College and M.D. from Tufts University School of Medicine, and his post graduate training in Internal Medicine and in Pathology. In addition, he did research in immunology at the Weizmann Institute of Science. Dr. Waksal was a founder of Imclone Systems Incorporated; a New York based pharmaceutical company specializing in developing new treatment for various forms of cancer. He served as the Chief Operating Officer and member of the Board of Directors from 1986 until 2001 and as President/CEO from 2001 until 2002. During his tenure, he was responsible for building the scientific and operation infrastructure of the company. Dr. Waksal is the author of over 50 scientific publications and has been the author of multiple patents and patent applications. His current activities are focused on managing various real estate developments and serving on select Board of Directors. Dr. Waksal currently serves on the Boards of the Oberlin College, Senesco Technologies, Inc. He also serves on the Advisory Board of Northern Rivers Funds.

Jean-Claude Debard

 Mr. Jean-Claude Debard is Independent Director of Neptune Technologies & Bioressources Inc., since 2009. Mr. Jean-Claude Debard has been President of M Motors Automobiles France, Subaru France, Daihatsu France, SsangYong France since 2012 and Executive President of Group Emil Frey France since 2008.

Daniel Perry

 Mr. Daniel Perry is Independent Director of Neptune Technologies & Bioressources Inc., since 2000. Since March 1993, Mr. Daniel Perry has been General Manager of companies operating recreational/tourism complexes in France. Mr. Perry is also a specialist and consultant for different corporations involved in the marketing of new products in Europe.

Basic Compensation

Name Fiscal Year Total

Ronald Denis

 --

Henri Harland

 339,000

Andre Godin

 210,000

Michel Chartrand

 432,538

Fotini Sampalis

 81,000

Harlan Waksal

 --

Jean-Claude Debard

 --

Daniel Perry

 --
As Of 28 Feb 2012

Options Compensation

Name Options Value

Ronald Denis

 0 0

Henri Harland

 1,206,000 2,000,710

Andre Godin

 564,250 1,063,527

Michel Chartrand

 0 0

Fotini Sampalis

 859,250 1,957,375

Harlan Waksal

 0 0

Jean-Claude Debard

 0 0

Daniel Perry

 0 0

Insider Trading

» Full list on Insider Trading
Search Stocks